Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Insights into a PCSK9 structural groove: a harbinger of new drugs to reduce LDL-cholesterol.

× No keyword cloud information.

24 in total

1. The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications.

Authors: Suzanne Benjannet; David Rhainds; Josée Hamelin; Nasha Nassoury; Nabil G Seidah
Journal: J Biol Chem Date: 2006-08-15 Impact factor: 5.157

2. Proteolytic cleavage of antigen extends the durability of an anti-PCSK9 monoclonal antibody.

Authors: Krista M Schroeder; Thomas P Beyer; Ryan J Hansen; Bomie Han; Richard T Pickard; Victor J Wroblewski; Mark C Kowala; Patrick I Eacho
Journal: J Lipid Res Date: 2015-09-20 Impact factor: 5.922

3. Effect of mutations in the PCSK9 gene on the cell surface LDL receptors.

Authors: Jamie Cameron; Øystein L Holla; Trine Ranheim; Mari Ann Kulseth; Knut Erik Berge; Trond P Leren
Journal: Hum Mol Genet Date: 2006-03-28 Impact factor: 6.150

4. Intensive lipid lowering with atorvastatin in patients with stable coronary disease.

Authors: John C LaRosa; Scott M Grundy; David D Waters; Charles Shear; Philip Barter; Jean-Charles Fruchart; Antonio M Gotto; Heiner Greten; John J P Kastelein; James Shepherd; Nanette K Wenger
Journal: N Engl J Med Date: 2005-03-08 Impact factor: 91.245

5. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.

Authors: Marianne Abifadel; Mathilde Varret; Jean-Pierre Rabès; Delphine Allard; Khadija Ouguerram; Martine Devillers; Corinne Cruaud; Suzanne Benjannet; Louise Wickham; Danièle Erlich; Aurélie Derré; Ludovic Villéger; Michel Farnier; Isabel Beucler; Eric Bruckert; Jean Chambaz; Bernard Chanu; Jean-Michel Lecerf; Gerald Luc; Philippe Moulin; Jean Weissenbach; Annick Prat; Michel Krempf; Claudine Junien; Nabil G Seidah; Catherine Boileau
Journal: Nat Genet Date: 2003-06 Impact factor: 38.330

6. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype.

Authors: Kara N Maxwell; Jan L Breslow
Journal: Proc Natl Acad Sci U S A Date: 2004-04-26 Impact factor: 11.205

7. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation.

Authors: Da-Wei Zhang; Thomas A Lagace; Rita Garuti; Zhenze Zhao; Meghan McDonald; Jay D Horton; Jonathan C Cohen; Helen H Hobbs
Journal: J Biol Chem Date: 2007-04-23 Impact factor: 5.157

8. Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials.

Authors: Evan A Stein; Robert P Giugliano; Michael J Koren; Frederick J Raal; Eli M Roth; Robert Weiss; David Sullivan; Scott M Wasserman; Ransi Somaratne; Jae B Kim; Jingyuan Yang; Thomas Liu; Moetaz Albizem; Rob Scott; Marc S Sabatine
Journal: Eur Heart J Date: 2014-03-04 Impact factor: 29.983

9. Identification of a small peptide that inhibits PCSK9 protein binding to the low density lipoprotein receptor.

Authors: Yingnan Zhang; Charles Eigenbrot; Lijuan Zhou; Steven Shia; Wei Li; Clifford Quan; Jeffrey Tom; Paul Moran; Paola Di Lello; Nicholas J Skelton; Monica Kong-Beltran; Andrew Peterson; Daniel Kirchhofer
Journal: J Biol Chem Date: 2013-11-13 Impact factor: 5.157

Review 3. The Multifaceted Biology of PCSK9.

Authors: Nabil G Seidah; Annik Prat
Journal: Endocr Rev Date: 2022-05-12 Impact factor: 25.261

3 in total

Insights into a PCSK9 structural groove: a harbinger of new drugs to reduce LDL-cholesterol.